Suppr超能文献

左旋甲状腺素剂量调整以优化患者终生的治疗。

Levothyroxine Dose Adjustment to Optimise Therapy Throughout a Patient's Lifetime.

机构信息

Unit of Endocrinology, Diabetes, and Metabolism, Thyroid Section, Evgenidion Hospital, Athens, Greece.

Division of Endocrinology, Georgetown University, Washington, DC, USA.

出版信息

Adv Ther. 2019 Sep;36(Suppl 2):30-46. doi: 10.1007/s12325-019-01078-2. Epub 2019 Sep 4.

Abstract

Levothyroxine is the standard therapy for patients with hypothyroidism, a condition that affects up to 5% of people worldwide. While levothyroxine therapy has substantially improved the lives of millions of hypothyroid patients since its introduction in 1949, the complexity of maintaining biochemical and clinical euthyroidism in patients undergoing treatment with levothyroxine cannot be underestimated. Initial dosing of levothyroxine can vary greatly and may be based on the amount of residual thyroid function retained by the patient, the body weight or lean body mass of the patient, and thyroid-stimulating hormone levels. As levothyroxine is usually administered over a patient's lifetime, physiological changes throughout life will affect the dose of levothyroxine required to maintain euthyroidism. Furthermore, dose adjustments may need to be made in patients with concomitant medical conditions, in patients taking certain medications, as well as in elderly patients. Patients who have undergone any weight or hormonal changes may require dose adjustments, and the majority of pregnant women require increased doses of levothyroxine. Optimal treatment of hypothyroidism requires a partnership between patient and physician. The physician is tasked with vigilant appraisal of the patient's status based on a thorough clinical and laboratory assessment and appropriate adjustment of their levothyroxine therapy. The patient in turn is tasked with medication adherence and reporting of symptomatology and any changes in their medical situation. The goal is consistent maintenance of euthyroidism, without the patient experiencing the adverse events and negative health consequences of under- or overtreatment.Funding Merck.Plain Language Summary Plain language summary available for this article.

摘要

左甲状腺素是治疗甲状腺功能减退症患者的标准疗法,这种疾病影响着全球多达 5%的人群。虽然自 1949 年左甲状腺素问世以来,它极大地改善了数百万甲状腺功能减退症患者的生活,但维持接受左甲状腺素治疗的患者生化和临床甲状腺功能正常的复杂性不容忽视。左甲状腺素的初始剂量差异很大,可能基于患者保留的甲状腺功能量、患者的体重或去脂体重以及促甲状腺激素水平。由于左甲状腺素通常在患者的一生中使用,因此整个生命周期中的生理变化会影响维持甲状腺功能正常所需的左甲状腺素剂量。此外,患有合并症的患者、服用某些药物的患者以及老年患者可能需要调整剂量。体重或激素变化的患者可能需要调整剂量,大多数孕妇需要增加左甲状腺素的剂量。甲状腺功能减退症的最佳治疗需要患者和医生之间的合作。医生的任务是根据全面的临床和实验室评估,警惕地评估患者的状况,并适当调整他们的左甲状腺素治疗。患者则需要坚持服药,并报告症状以及其医疗状况的任何变化。目标是始终保持甲状腺功能正常,而不会出现治疗不足或过度治疗带来的不良反应和对健康的负面影响。

资助

默克。

本文提供通俗易懂的概要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验